P2X7 receptor activation ameliorates CA3 neuronal damage via a tumor necrosis factor-α-mediated pathway in the rat hippocampus following status epilepticus

J Neuroinflammation. 2011 Jun 2:8:62. doi: 10.1186/1742-2094-8-62.

Abstract

Background: The release of tumor necrosis factor-α (TNF-α) appears depend on the P2X7 receptor, a purinergic receptor. In the present study, we addressed the question of whether P2X7 receptor-mediated TNF-α regulation is involved in pathogenesis and outcome of status epilepticus (SE).

Methods: SE was induced by pilocarpine in rats that were intracerebroventricularly infused with saline-, 2',3'-O-(4-benzoylbenzoyl)-adenosine 5'-triphosphate (BzATP), adenosine 5'-triphosphate-2',3'-dialdehyde (OxATP), A-438079, or A-740003 prior to SE induction. Thereafter, we performed Fluoro-Jade B staining and immunohistochemical studies for TNF-α and NF-κB subunit phosphorylations.

Results: Following SE, P2X7 receptor agonist (BzATP) infusion increased TNF-α immunoreactivity in dentate granule cells as compared with that in saline-infused animals. In addition, TNF-α immunoreactivity was readily apparent in the mossy fibers, while TNF-α immunoreactivity in CA1-3 pyramidal cells was unaltered. However, P2X7 receptor antagonist (OxATP-, A-438079, and A-740003) infusion reduced SE-induced TNF-α expression in dentate granule cells. In the CA3 region, BzATP infusion attenuated SE-induced neuronal damage, accompanied by enhancement of p65-Ser276 and p65-Ser311 NF-κB subunit phosphorylations. In contrast, OxATP-, A-438079, and A-740003 infusions increased SE-induced neuronal death. Soluble TNF p55 receptor (sTNFp55R), and cotreatment with BzATP and sTNFp55R infusion also increased SE-induced neuronal damage in CA3 region. However, OxATP-, sTNFp55R or BzATP+sTNFp55R infusions could not exacerbate SE-induced neuronal damages in the dentate gyrus and the CA1 region, as compared to BzATP infusion.

Conclusions: These findings suggest that TNF-α induction by P2X7 receptor activation may ameliorate SE-induced CA3 neuronal damage via enhancing NF-κB p65-Ser276 and p65-Ser311 phosphorylations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetamides / pharmacology
  • Adenosine Triphosphate / analogs & derivatives
  • Adenosine Triphosphate / pharmacology
  • Animals
  • CA3 Region, Hippocampal / cytology
  • CA3 Region, Hippocampal / drug effects
  • CA3 Region, Hippocampal / metabolism
  • CA3 Region, Hippocampal / pathology*
  • Male
  • Muscarinic Agonists / pharmacology
  • Neurons / drug effects
  • Neurons / metabolism
  • Neurons / pathology*
  • Pilocarpine / pharmacology
  • Purinergic Agonists / pharmacology
  • Purinergic Antagonists / pharmacology
  • Pyridines / pharmacology
  • Quinolines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Purinergic P2X7 / metabolism*
  • Signal Transduction / physiology*
  • Status Epilepticus / chemically induced
  • Status Epilepticus / metabolism*
  • Tetrazoles / pharmacology
  • Transcription Factor RelA / metabolism
  • Tumor Necrosis Factor-alpha / metabolism*

Substances

  • (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide)
  • 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine
  • Acetamides
  • Muscarinic Agonists
  • Purinergic Agonists
  • Purinergic Antagonists
  • Pyridines
  • Quinolines
  • Receptors, Purinergic P2X7
  • Rela protein, rat
  • Tetrazoles
  • Transcription Factor RelA
  • Tumor Necrosis Factor-alpha
  • Pilocarpine
  • 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate
  • Adenosine Triphosphate